About Enhancer
| Enhancer ID: | E_01_0455 |
| Species: | human |
| Position : | chr11:32384629-32386629   |
| Biosample name: | |
| Experiment class : | High+Lowthroughput |
| Enhancer type: | Enhancer |
| Disease: | Cholangiocarcinoma |
| Pubmed ID: | 29790264 |
| Enhancer experiment: | ELISPOT,PCR,real-time PCR,Immunotherapy |
| Enhancer experiment description: | These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy. |
About Target gene
| Target gene : | WT1(AWT1,GUD,NPHS4,WAGR,WIT-2,WT33),MUC5AC,GPC3,KIF20A |
| Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
| Less strong evidence: | RNA-Seq |
| Target gene experiment description: | These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy.;These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy.;These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy.;These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy.;These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy. |
About TF
| TF name : | EZH2(ENX-1,ENX1b,KMT6,KMT6A,WVS,WVS2,EZH2) |
| TF experiment: | ELISPOT,PCR,real-time PCR,Immunotherapy |
| TF experiment description: | These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy.;These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy.;These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy.;These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy.;These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy. |
About Function
| Enhancer function : | These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy. |
| Enhancer function experiment: | Immunohistochemical staining |
| Enhancer function experiment description: |
These results demonstrated several TAAs may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy. |
About SNP
| SNP ID: | -- |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| EZH2 | Activation of anterior HOX genes in hindbrain development during early embryogenesis | reactome | 120 |
| EZH2 | Oxidative Stress Induced Senescence | reactome | 120 |
| EZH2 | PKMTs methylate histone lysines | reactome | 64 |
| EZH2 | PRC2 methylates histones and DNA | reactome | 71 |
| EZH2 | Hs_Endoderm_Differentiation_WP2853_88152 | wikipathways | 62 |
| EZH2 | Hs_Interactome_of_polycomb_repressive_complex_2_(PRC2)_WP2916_88672 | wikipathways | 15 |
Enhancer associated network
The number on yellow line represents the distance between enhancer and
target gene